Co-Diagnostics (STU:C97) FCF Margin % : -199.64% (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Co-Diagnostics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Co-Diagnostics's Free Cash Flow for the three months ended in Jun. 2024 was €-4.93 Mil. Co-Diagnostics's Revenue for the three months ended in Jun. 2024 was €2.47 Mil. Therefore, Co-Diagnostics's FCF Margin % for the quarter that ended in Jun. 2024 was -199.64%.

As of today, Co-Diagnostics's current FCF Yield % is -67.78%.

The historical rank and industry rank for Co-Diagnostics's FCF Margin % or its related term are showing as below:

STU:C97' s FCF Margin % Range Over the Past 10 Years
Min: -41750 Med: -1483.27 Max: 41.28
Current: -284.88

During the past 9 years, the highest FCF Margin % of Co-Diagnostics was 41.28%. The lowest was -41750.00%. And the median was -1483.27%.

STU:C97's FCF Margin % is ranked worse than
86.11% of 828 companies
in the Medical Devices & Instruments industry
Industry Median: -6.365 vs STU:C97: -284.88

Co-Diagnostics FCF Margin % Historical Data

The historical data trend for Co-Diagnostics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Co-Diagnostics FCF Margin % Chart

Co-Diagnostics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-2,615.98

36.74

41.29

15.02

-344.18

Co-Diagnostics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
FCF Margin %	Get a 7-Day Free Trial															-3,079.23	-244.31	-147.48	-3,511.16	-199.64

Competitive Comparison of Co-Diagnostics's FCF Margin %

For the Medical Devices subindustry, Co-Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Co-Diagnostics's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Co-Diagnostics's FCF Margin % falls into.

Co-Diagnostics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Co-Diagnostics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-21.501	/	6.247
	=	-344.18 %

Co-Diagnostics's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-4.927	/	2.468
	=	-199.64 %

Co-Diagnostics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Co-Diagnostics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Co-Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (STU:C97) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CODX:USA 0A50:UK C97:Germany

Address

2401 South Foothill Drive, Salt Lake City, UT, USA, 84109

Website

https://www.codiagnostics.com

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Co-Diagnostics Headlines

No Headlines